Factory Direct Anti-Estrogen Steroid Raloxifene HCl / Raloxifene Hydrochloride
CAS 82640-04-8 Raloxifene hydrochloride
|Alias:||Raloxifene hydrochloride,Raloxifene HCl|
|Appearance:||white crystalline powder|
Use in Cancer
Raloxifene hydrochloride is approved to prevent:
Breast cancer. It is used to decrease the chance of invasive breast cancer in postmenopausal women who have a high risk for developing the disease or who have osteoporosis.
The role of raloxifene in the prevention and treatment of breast cancer is currently under investigation. There is also a similar mechanism of action of drugs, tamoxifen (tamoxifen), for the treatment of breast cancer has been a long time. It is hoped that Raloxifene will be as effective as tamoxifen with less adverse effects.
Raloxifene (marketed as Evista) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women and to reduce the risk of invasive breast cancer in postmenopausal women with osteoporosis and in postmenopausal women at high risk for invasive breast cancer.
This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass, but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.
Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. It is also used for reduction of risk and treatment of invasive breast cancer, and it also reduces breast density.For either osteoporosis treatment or prevention, supplemental calcium and/or vitamin D should be added to the diet if daily intake is inadequate.
Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.
Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.
|Contact Person :||Lisa|